Sugi Predict

Sugi Predict / Compounds / SCHEMBL31748294

SCHEMBL31748294

SCHEMBL31748294

CC[C@H](C)[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 14/20 0.67
▸ BACE2 Q9Y5Z0 4/20 0.58
▸ CTSD P07339 1/20 0.56
▸ KISS1R Q969F8 2/20 0.56
▸ TASP1 Q9H6P5 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30512615 0.90 BACE1 (0.59) BACE1BACE2CTSDKISS1R
SCHEMBL30512567 0.89 VIPR1 (0.60) BACE1KISS1R
SCHEMBL30974316 0.87 VIPR1 (0.60) BACE1BACE2CTSDKISS1R
SCHEMBL15094182 0.87 BACE1 (0.58) BACE1BACE2CTSDKISS1R
SCHEMBL15094185 0.87 BACE1 (0.58) BACE1CTSDKISS1R
SCHEMBL30589933 0.86 BACE1 (0.67) BACE1BACE2CTSD
SCHEMBL38660823 0.86 TASP1 (0.61) BACE1BACE2CTSDTASP1
SCHEMBL30504288 0.86 BACE1 (0.58) BACE1CTSDKISS1R
SCHEMBL29450265 0.86 BACE1 (0.58) BACE1CTSDKISS1R
SCHEMBL31514376 0.86 BACE1 (0.65) BACE1BACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102461-A1 PROTEIN SCAFFOLDS FOR DISORDERED REGIONS AIKIUM INC (US) 2026-04-16 — — US disclosed
US-20250387450-A1 PROTEIN SCAFFOLDS FOR DISORDERED REGIONS AIKIUM INC (US) 2025-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250387450-A1 PROTEIN SCAFFOLDS FOR DISORDERED REGIONS SPPL2B, SPPL2A, CRYZ BACE1 729/4885BACE2 1145/4885CTSD 1283/4885
US-20260102461-A1 PROTEIN SCAFFOLDS FOR DISORDERED REGIONS MAX, CRYZ, STAMBP BACE1 125/4885BACE2 306/4885CTSD 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback